Department of Immunology, Faculty and Graduate School of Medicine, Mie University, Edobashi 2-174, Tsu, Mie 514-8507, Japan.
Department of Diabetes and Endocrinology, Faculty and Graduate School of Medicine, Mie University, Edobashi 2-174, Tsu, Mie 514-8507, Japan.
Int J Mol Sci. 2018 Sep 25;19(10):2902. doi: 10.3390/ijms19102902.
Crizotinib is highly effective against anaplastic lymphoma kinase-positive and c-ros oncogen1-positive non-small cell lung cancer. Renal dysfunction is associated with crizotinib therapy but the mechanism is unknown. Here, we report a case of anaplastic lymphoma kinase positive non-small cell lung cancer showing multiple cysts and dysfunction of the kidneys during crizotinib administration. We also present results demonstrating that long-term crizotinib treatment induces fibrosis and dysfunction of the kidneys by activating the tumor necrosis factor-α/nuclear factor-κB signaling pathway. In conclusion, this study shows the renal detrimental effects of crizotinib, suggesting the need of careful monitoring of renal function during crizotinib therapy.
克唑替尼对间变性淋巴瘤激酶阳性和 c-ros 原癌基因 1 阳性非小细胞肺癌具有高度疗效。肾功能障碍与克唑替尼治疗相关，但机制尚不清楚。在这里，我们报告了一例间变性淋巴瘤激酶阳性非小细胞肺癌患者在接受克唑替尼治疗期间出现多个囊肿和肾功能障碍。我们还提供了结果表明，长期克唑替尼治疗通过激活肿瘤坏死因子-α/核因子-κB 信号通路诱导肾脏纤维化和功能障碍。总之，本研究表明克唑替尼具有肾脏损害作用，提示在克唑替尼治疗期间需要仔细监测肾功能。
